Loading...
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers
In breast cancer cells with HER2 gene amplification, HER2 receptors exist on the cell surface as monomers, homodimers and heterodimers with EGFR/HER3. The therapeutic antibody trastuzumab, an approved therapy for HER2+ breast cancer, cannot block ligand-induced HER2 heterodimers, suggesting it canno...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3221734/ https://ncbi.nlm.nih.gov/pubmed/21324925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-1872 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|